Positive developments across policy, industry, pharmaceutical companies, AIDD, and corporate performance are resonating together.
Is innovative drugs still the key theme to watch in the fourth quarter?
Full-chain positioning in innovative drugs, pay attention to T+0 trading tools.
Hong Kong Stock Connect Innovative Drug ETF Huabao #520880 offers 100% exposure to innovative drug R&D companies.
Hong Kong Stock Connect Healthcare ETF Huabao #159137 has over 50% CXO allocation.
MACD golden cross signals have formed, and these stocks are showing strong gains.